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Abstract 
 
Members of the formin family are known to be involved in the regulation of the 
actin cytoskeleton. We have recently identified a muscle specific splice variant 
of the formin FHOD3 and demonstrated its role in the maintenance of the 
contractile filaments of cardiomyocytes. Here we characterise the expression 
and subcellular localisation of FHOD3's closest relative, FHOD1, in the heart. 
Confocal microscopy shows that FHOD1 is mainly located at the intercalated 
disc, the special type of cell-cell contact between cardiomyocytes, but also 
partially associated with the myofibrils. Subcellular targeting of FHOD1 is 
probably mediated by its N-terminal domain, since expression constructs 
lacking this domain show aberrant localisation in primary cultures of neonatal 
rat cardiomyocytes. Finally we show that in contrast to FHOD3, FHOD1 
shows increased expression levels in dilated cardiomyopathy, suggesting that 
the two formins play distinct roles and are differentially regulated in 
cardiomyocytes. 
 
 
Introduction 
 
Cardiomyocytes, which make up the bulk of heart mass, are characterised by 
an exquisitely organised cytoskeleton, which is the basis of maximal 
functional output (Ehler, 2010). The actin cytoskeleton comprises the thin 
filaments in the myofibrils, which mediate muscle contraction together with the 
thick (myosin) filaments, but in addition plays also a role in the organisation of 
the plasma membrane cytoskeleton as well as in the anchoring of myofibrils at 
the specialised type of cell-cell contact in heart tissue, the intercalated disc 
(Dwyer et al., 2012). Despite this crucial role of actin in the function of 
cardiomyocytes, it is subjected to an impressive amount of protein turnover. 
Measurements in rat hearts have suggested that actin has a half-life of about 
10 days (Martin, 1981). How the exchange of actin molecules is achieved in 
the continuously working cardiomyocyte is not well understood. 
We have recently focused our attention on a potential role of formins in the 
heart. Formins are proteins, which are mainly involved in the formation of 
linear actin filaments (Chesarone et al., 2010). They are characterised by the 
possession of an FH1 and an FH2 domain (for domain layout of formins see 
Figure 1), which together make up the actin capturing and polymerisation 
machinery and so far 15 different formins were described in mammals 
(Schönichen and Geyer, 2010).  
One characteristic of formins is that they normally exist in an autoinhibited 
state, which is brought about by an intramolecular interaction between the N-
terminal DID and the C-terminal DAD domain. Binding of a small GTPase 
within the N-terminus and/or phosphorylation of the C-terminus by ROCK 
were documented as being prerequisites in the activation of these molecules 
(Chesarone et al., 2010). 
One of the formins, Daam1, was shown to be crucial for early heart 
development (Li et al., 2011) and we have recently demonstrated that another 
one, FHOD3, is required for myofibril maintenance (Iskratsch et al., 2010). 
FHOD3 exists in several splice variants, one of which is subject to regulation 
by CK2 phosphorylation and is expressed exclusively in striated muscle 
(Katoh and Katoh, 2004; Iskratsch et al., 2010). Interestingly, the 
downregulation of the expression of this isoform accompanies the phenotype 
of murine and human dilated cardiomyopathy (Iskratsch et al., 2010). 
The closest relative of FHOD3, FHOD1 has so far mainly been studied in 
cultured cells. It was initially shown to be involved in stress fibre formation as 
well as in plasma membrane blebbing (Gasteier et al., 2003; Hannemann et 
al., 2008). In addition, FHOD1 was shown to activate transcription from the 
serum responsive element (Westendorf, 2001). More recently it was 
demonstrated that FHOD1 may actually have more an actin bundling than a 
classical nucleating activity (Schönichen et al., 2013). Furthermore its role in 
cell spreading and adhesion maturation was discovered recently (Iskratsch et 
al., 2013a). Studies in smooth muscle have shown that FHOD1 is involved in 
the regulation of differentiation and that high levels of expression are required 
to maintain the expression of smooth muscle marker proteins (Staus et al., 
2011). In that study, analysis of the tissue expression of FHOD1 
demonstrated high levels in bladder and stomach, low levels in aorta and in 
skeletal muscle and no expression in the heart (Staus et al., 2011). 
Our own analysis of heart tissue using several different antibodies 
demonstrate that FHOD1 is expressed in cardiomyocytes at similar levels as 
in skeletal muscle and that it is mainly located at the intercalated disc. In 
analogy to many other formins our data indicates that FHOD1ʼs subcellular 
targeting is mediated by its N-terminal domain. In contrast to our observations 
for FHOD3, we find increased expression levels of FHOD1 in dilated 
cardiomyopathy, suggesting diverging roles and regulation of those two 
formins. 
 
 
Material and Methods 
 
Murine and human samples 	  
Adult male C57/BL6 wild type and MLP-/- mice (Arber et al., 1997) were used 
for tissues in Western Blot analysis and immunofluorescence studies. 
Experiments were performed in accordance with the Guidance on the 
Operation of Animals (Scientific Procedures) Act, 1986 (UK). Prior to 
harvesting tissues, mice were sacrificed by cervical dislocation. Tissues for 
cryosectioning were snap frozen in methylbutane in liquid nitrogen. For SDS 
samples, tissues were frozen in liquid nitrogen, pulverised, and lysed in SDS 
lysis buffer (130mM Tris, 190mM SDS, 3.69M urea, 0.06% NP40, 0.17%β-
mercaptoethanol, 3.85% glycerol and 0.01% bromphenol blue at pH 6.8) 
(Iskratsch et al., 2010).  For immunofluorescence staining, the hearts were 
sectioned on a Leica CM1950 cryostat (Leica, Wetzlar, Germany) into 12μm 
sections, mounted on poly-L-lysine coated microscope slides, fixed with pre-
cooled acetone (-20°C) for 5min followed by antibody staining as described 
previously (Iskratsch et al., 2010). 
Human specimens were obtained from The University of Sydney, Australia via 
St Vincentʼs Hospital (Hospital Research Ethical Committee approval 
#H03/118; University of Sydney ethical approval #12146). Human materials 
were used in accordance with the ethical guidelines of Kingʼs College London 
(College Research Ethical Committee 04/05-74; REC reference 12/EM/0106) 
and the current UK law. 
 
Neonatal Rat Cardiomyocytes 
Neonatal rat cardiomyocytes (NRCs) were isolated from day 1 newborn 
Wistar rat pups.  NRCs were isolated using the Worthington Neonatal 
Cardiomyocyte Isolation System (Worthington Biochemical Corporation, 
Lakewood, NJ, USA) according to the manufacturerʼs instructions.  Cells were 
seeded onto PureCol® purified bovine collagen solution (Advanced BioMatrix, 
San Diego, CA, USA) coated 30mm dishes in NRC plating medium and 
cultured and immunostained as described previously (Iskratsch et al., 2010). 
Transient transfections were carried out using Escort III (Sigma-Aldrich) as a 
transfection reagent. 
 Antibodies 
All antibodies against FHOD1 were obtained from commercial sources. The 
polyclonal goat (pG) antibodies anti FHOD1 (C14; against a peptide within an 
internal region of FHOD1 and C20; against a peptide near the C-terminus of 
FHOD1) were from Santa Cruz (Dallas, TX, USA), the polyclonal mouse (pM) 
anti full length FHOD1 was from Abcam (Cambridge, UK) and the polyclonal 
rabbit (pR) anti FHOD1 Phospho-Threonine 1141 was from ECM Biosciences 
(Versailles, KY, USA). The pR anti-sarcomeric alpha-actinin was a kind gift 
from Prof. Dieter Fürst (University of Bonn, Germany).  The monoclonal 
mouse (mM) anti-myomesin (clone B4) antibody was produced in the lab 
(Grove et al., 1984) and the mM anti sarcomeric alpha-actinin (clone EA-53) 
was purchased from Sigma (Dorset, UK). The mM anti GFP (clones 7.1 and 
13.1) was bought from Roche (Burgess Hill, UK). The pR anti-NRAP antibody 
was generated by immunisation of rabbits with a peptide portion of NRAP by 
Bioscience (Göttingen, Germany).  All Cy-conjugated secondary antibodies 
were purchased from Jackson Immuno Research (West Grove, PA, USA) and 
only multi-labelling quality antibodies were employed.  The anti mouse HRP-
conjugated secondary antibodies were purchased from DAKO (Glostrup, 
Denmark) and the anti rabbit HRP-conjugated secondary antibodies were 
purchased from Chemicon (via Merck-Millipore, Billerica, MA, USA).  DAPI 
was obtained from Sigma and Alexa633-phalloidin was purchased from 
LifeTechnologies (Paisley, UK).  
 
Preparation of Transfection Constructs 
 
The full length long variant of FHOD1[1-1191] was amplified from human 
skeletal muscle cDNA (Clontech Laboratories), using LaTaq polymerase 
(TaKaRa Bio, Shiga, Japan) and the appropriate primers (synthesised by 
Eurofins MWG Operon, Ebersberg, Germany; Accession number used for 
FHOD1: XM_005255909.1 in March 2008; see also (Tojo et al., 2003) and 
(Iskratsch et al., 2013a).  FHOD1 ΔDAD [1-1096] and the FHOD1 domain 
constructs (FH2, GBD-DID, GBD, and DID) were amplified using the full 
length FHOD1 [1-1191] construct DNA as a template. The following primer 
sets were used: FHOD1 [1-1191] fwd 
5ʻGGAATTCATGGCGGGCGGGGAAGAC3ʼ, rev 3ʼ 
GGGGTACCCACCTCCAGGCCAGGACC5ʼ; FHOD1 deltaDAD [1-1096] fwd 
5ʻGGAATTCATGGCGGGCGGGGAAGAC3ʼ, rev 
3'GGGGTACCGGCGATTGTGTGTGGTG5'; FHOD1-FH2 [642-1031] fwd 5ʼ 
GGAATTCGACAGCTCAGCCCTCCCC3ʼ, rev 
3ʼGGGGTACCGGCGATTGTGTGTGGTG5ʼ; FHOD1-GBD [1-116] fwd 
5ʻGGAATTCATGGCGGGCGGGGAAGAC3ʼ, rev 
3ʼGGGGTACCAAGATAGCGTTGACCCTC5ʼ; FHOD1-GBD-DID [1-340] fwd 
5ʼGGAATTCATGGCGGGCGGGGAAGAC3ʼ, rev 
3ʼGGGGTACCTTCTTCGATGTCTCCATC5ʼ; FHOD1 DID [117-340] fwd 
5ʼGGAATTCTACCCAGCTCTCTGTGAGG3ʼ, rev 
3ʼGGGGTACCTTCTTCGATGTCTCCATC5ʼ. The DNA fragments amplified 
from PCR were cloned into the pEGFP-C1 and pEGFP-C2 (Clontech/TaKaRa 
Bio, Shiga, Japan) vectors for eventual expression as N-terminally tagged 
green fluorescent fusion proteins via the EcoRI and KpnI sites. All constructs 
were verified by sequencing (Eurofins MWG Operon, Ebersberg, Germany).   
Verification of correct expression of the constructs was additionally carried out 
by transiently transfecting COS cells using Escort IV as a transfection reagent 
and analyzing the molecular weight of the GFP-fusion proteins by 
immunoblots as described below. 
 
SDS-PAGE and immunoblotting, immunofluorescence and confocal 
microscopy 
 
Sample preparation, SDS-PAGE and immunoblotting were all performed as 
described previously (Iskratsch et al., 2010). Immunoreactions on the blots 
were visualised by chemiluminescence using horse radish peroxidase-
conjugated secondary antibodies against mouse or rabbit immunoglobulins 
and the signal was detected either conventionally with X-ray films or using a 
Fusion Solo Detector (Vilber Lourmat, Marne La Vallee, France). 
Immunostaining of frozen sections and fixed neonatal rat cardiomyocytes 
were all carried out as before (Iskratsch et al., 2010). All confocal microscopy 
was performed on a LSM510 laser scanning confocal microscope (Carl Zeiss 
MicroImaging GmbH, Jena, Germany) or an SP5 laser scanning confocal 
microscope (Leica Microsystems, Mannheim, Germany) with solid state 
(diode) laser excitation at 405 nm and emission at 420-480 nm, Ar-laser 
excitation at 488 nm and emission at 505-530 nm or He-Ne-laser excitation at 
546 and 633 nm and emission at 560-615 nm and > 650 nm using Plan-
Apochromat 63x/1.4 oil objectives or Plan-Neofluar 40x/0.9 oil objectives. 
Digital images were processed and assembled to figures in Photoshop 
(Adobe Systems, San Jose, CA, USA). 
 
 
Results 
 
In order to investigate the expression of FHOD1 at tissue level, we performed 
immunoblots with FHOD1 specific antibodies. We used only commercially 
available antibodies, however, due to the high levels of homology between 
forming family members and based on potential cross-reactivity of polyclonal 
antisera with other muscle proteins (for example see Wang et al., 2012), we 
decided to evaluate the specificity of our reagents first. Immunocytochemistry 
and immunoblots on COS cells that were transiently transfected with FHOD1 
and FHOD3 constructs clearly showed that the anti FHOD1 antibodies that we 
used only recognised FHOD1 and did not cross-react with FHOD3 (Figure 2A, 
B). The antibody (pR anti FHOD1 pThr1141) that was used for most of the 
immunohistochemistry experiments was additionally evaluated on NRC 
overexpressing full length and C-terminally truncated FHOD1 (FHOD1-
deltaDAD) and while it gave a clear signal for full length FHOD1 it failed to 
detect the C-terminally truncated version, which lacks Thr1141 (Figure 3). In 
addition, the antibody did not pick up any cross-striated pattern in the NRC, 
suggesting that it does not cross-react with well-known problematic proteins 
such as sarcomeric alpha-actinin or sarcomeric myosin (Figure 3). We 
therefore proceeded to study FHOD1 expression by immunoblot on whole 
muscle samples from mouse. As expected, a prominent band was seen in 
spleen (Westendorf et al., 1999; Tojo et al., 2003), which was used as a 
positive control, but a band of the same molecular weight was also detected in 
heart, as well as in fast and slow twitch skeletal muscle (Tibialis anterior, TA, 
and Soleus, respectively, Figure 4). Expression of sarcomeric alpha-actinin 
was used as a loading control and suggested that expression of FHOD1 is 
higher in heart and fast twitch than in slow twitch muscle. To investigate the 
subcellular localisation of FHOD1, immunohistochemistry on frozen sections 
followed by confocal microscopy analysis was performed. With three different 
FHOD1 antibodies that are directed against three different epitopes along the 
molecule, a strong signal was seen in cardiomyocytes, which was mainly 
concentrated at the specific sites of cell-cell contact in heart, the intercalated 
discs (Figure 5). Occasionally a cross-striated pattern was seen, suggesting 
some association of FHOD1 with myofibrils. Counterstaining for the M-band 
marker myomesin revealed alternating striations and indicates that FHOD1 
may be present in some of the Z-discs. Interestingly this localisation pattern 
may be evolutionally conserved, since also C. elegans FHOD1 is found as 
bright puncta at the muscle cell edges with faint striations at the dense bodies, 
the equivalent of the Z-disc (Mi-Mi et al., 2012). The three different antibodies 
revealed grossly similar staining patterns in heart sections and also the signal 
with the antibody that is expected to detect only active FHOD1, which is 
phosphorylated on Threonine 1141, looked comparable to the results 
obtained with the antibodies that detect all FHOD1 (compare Figure 5C with 
A, B). Together these results demonstrate FHOD1 expression in 
cardiomyocytes, where it is predominantly found at the intercalated disc. 
Next we wanted to analyse the effect of overexpression of FHOD1 on the 
cytoarchitecture of primary cultures of neonatal rat cardiomyocytes (NRC). 
Expression tests of the GFP-tagged constructs in transiently transfected COS 
cells followed by immunoblotting revealed that GFP fusion proteins of the 
expected molecular weight were generated and that also the expression 
levels are roughly similar between constructs, apart from lower expression 
levels for the C-terminal deletion construct (deltaDAD; Figure 6). Transient 
expression of full length and constitutively active (by means of truncation of its 
C-terminal DAD domain) GFP-tagged FHOD1 was carried out in NRC and the 
effect on the myofibrils and the actin cytoskeleton was investigated by 
confocal microscopy. Full length FHOD1 again shows a predominant 
localisation at the periphery of the cells (Figure 7A). In addition, there was a 
lot of diffuse cytoplasmic signal with hardly any visible signs of cross-
striations. No increased signal was seen at the cell-cell contacts between the 
NRC. Overexpression of constitutively active FHOD does not seem to affect 
the organisation of the myofibrils as indicated by their sarcomeric alpha-
actinin signal. However, there was evidence for increased levels of 
filamentous actin, compared to untransfected control cells (Figure 7B). This 
suggests that while overexpression of full length FHOD1 is well tolerated and 
has little effect on cytoarchitecture, increased expression of active FHOD1 
may lead to increased actin filament formation, similar to observations that 
were made using constitutively active FHOD3 (Iskratsch et al., 2013b). 
The subcellular targeting of formins is often mediated by their N-terminus 
(Seth et al., 2006; Ramalingam et al., 2010), which also tends to be the part of 
the molecule with the highest divergence in its sequence and even in its 
structure (Schulte et al., 2008). We created GFP-tagged expression 
constructs that only encoded for subdomains of FHOD1 and analysed their 
subcellular targeting in NRC. The FH2 domain of FHOD1 on its own displays 
a strong signal at the Z-disc, as indicated by its alternation with signal for the 
M-band protein myomesin (Figure 8A). Constructs encoding the GBD-DID 
domain or even only the GBD domain on its own show mainly diffuse 
cytoplasmic localisation with some evidence for myofibril association (Figure 
8B, D; for scheme of the constructs see Figure 1). DID alone as well as an N-
terminal deletion construct lacking the GBD domain either showed aggregates 
or small vesicular-like structures. These experiments suggest that the GBD 
domain of FHOD1 mediates the subcellular targeting that is observed for full 
length FHOD1 in NRC. 
Our previous studies had demonstrated that the expression of the closest 
relative of FHOD1, FHOD3, is downregulated in dilated cardiomyopathy 
(Iskratsch et al., 2010). Interestingly this was not seen when the expression of 
FHOD1 was analysed in MLP knockout mice, a mouse model for dilated 
cardiomyopathy (Arber et al., 1997). In fact the signal of FHOD1 at the 
intercalated disc even seems to be increased, in a similar way to the signal for 
N-RAP, which was previously shown to be an early marker for dilated 
cardiomyopathy (Figure 9A; Ehler et al., 2001). This increase in FHOD1 
expression could also be reproduced in human DCM samples compared to 
controls (Figure 9B). Therefore, the formins FHOD1 and FHOD3 seem to play 
distinct roles in DCM, one being up- the other being downgulated. 
In conclusion we have demonstrated that the formin FHOD1 is expressed in 
heart and that it localises mainly at the intercalated disc. In DCM the signal for 
FHOD1 at the intercalated discs is increased, probably due to increased 
membrane convolution and may indicate a potential role of FHOD1 in the 
formation of actin anchoring structures. 
 
 
Discussion 
 
This study focused on the formin FHOD1 and shows its expression and 
subcellular localisation in cardiomyocytes. Previous studies had cast doubt on 
the expression of FHOD1 in heart (Staus et al., 2011), but we show here with 
several different antibodies that we can visualise FHOD1 in cardiomyocytes 
and get consistent results. Since we have validated the reactivity of these 
antibodies and their lack of cross-reaction with FHOD3 using expression 
constructs (Figure 2), we are confident that they do detect endogenous 
FHOD1 and that the signal is not due to a cross-reaction. Analysis of human 
FHOD1 expression at the mRNA level had previously suggested its presence 
in striated muscle tissue (reviewed in Randall and Ehler, 2013). Interestingly, 
slow twitch fibres appear to express lower levels of FHOD1 than either fast 
twitch fibres or the heart, which is in contrast to many other cytoskeletal 
proteins, which seem to be regulated in their expression in a similar way in 
ventricular and slow twitch muscle (Schiaffino and Reggiani, 1996). 
Overexpression of FHOD1 in NRC revealed a mainly diffuse signal with major 
intensities at the periphery of the cells. However, in contrast to the observed 
localisation for FHOD1 at the intercalated disc in heart tissue, we did not 
detect a consistently increased signal for FHOD1 at the cell-cell contacts 
between NRC. These contacts are often termed intercalated disc-like 
structures, since although the classical intercalated disc components such as 
desmosomal proteins and gap junction proteins can be identified there, one 
major difference is that they do not necessarily have to have end-on insertion 
of myofibrils but can also occur in parallel to myofibrils (Hirschy et al., 2006). 
Analysis of FHOD1 expression during embryonic heart development and 
comparison of its localisation with established intercalated disc anatomy will 
be required to determine, whether FHOD1 is only a late addition and 
characterises mature intercalated discs in the three-dimensional environment 
in situ. 
The expression of constitutively active FHOD1 induced a star-like phenotype 
in NRC. This is in contrast to overexpression of constitutively active FHOD3 in 
NRC, which lead to a massive increase in filamentous actin stretching 
throughout the cell (Iskratsch et al., 2013b). This observation together with the 
slightly different subcellular targeting and the dramatically different response 
of FHOD1 and FHOD3 to an insult such as dilated cardiomyopathy, highlight 
that despite their homology these two formins carry out distinct functions in 
cardiomyocytes. Their different subcellular targeting means that they regulate 
distinct sets of actin filaments and their expression is also regulated 
independently. These observations provide further evidence for the 
hypothesis that formins are not general actin filament polymerising factors but 
carry out subtly different, tightly regulated roles, that are hugely dependent on 
their subcellular targeting (Randall and Ehler, 2013). 
The localisation of FHOD1 at the intercalated disc and its upregulation in 
dilated cardiomyopathy are especially intriguing when recent findings on the 
role of the intercalated disc in cardiomyocyte growth are considered. Altered 
stoichiometry of intercalated disc proteins was suggested a decade ago to be 
among the hallmarks of dilated cardiomyopathy (Perriard et al., 2003) and 
many proteins were shown to be altered in their expression (Estigoy et al., 
2009). Interestingly, proteins that are involved in the anchoring of actin 
filaments always tend to be increased in their expression levels (Ehler et al., 
2001). The intercalated discs also attain a broader appearance, which is due 
to increased convolution of the contacting plasma membranes, similar to 
observations made in the aged heart (Forbes and Sperelakis., 1985). A recent 
study on a volume overload model in the rabbit has proposed the weaving 
sarcomere hypothesis, which means that sarcomeres are inserted at the 
terminals of the cardiomyocyte to increase its size, which leads to a transient 
splitting of the signal for intercalated disc proteins (Yoshida et al., 2010). This 
agrees well with the concept of the transitional junction (Bennett et al., 2006), 
which contains only a subset of Z-disc proteins and does not show increased 
electron density ultrastructurally. Via the transitional junction the actin 
filaments transgress with maintained polarity towards the intercalated disc 
(Yamaguchi et al., 1988).  Controlled insertion of sarcomeres in these regions 
was also documented during heart development and shown to be disturbed in 
dilated cardiomyopathy (Wilson et al., 2014). Increased actin anchorage 
together with the elevated levels of an actin nucleating and/or bundling protein 
such as FHOD1 may contribute to the imbalance of growth and eventually to 
the observed phenotypes in dilated cardiomyopathy. FHOD1 may thus not 
only be relevant for normal heart function but may also play a crucial role in 
heart disease. 
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Figure legends 
 
Figure 1: Schematic representation of the domain layout of FHOD1 and 
the FHOD1 constructs used for transient transfection into NRC. N-
terminally GFP-tagged full length FHOD1 including (A) or lacking the 
alternatively spliced exons 12 and 13 (B) and the respective deletion 
constructs (C-H). Domain borders are given in brackets. GBD GTPase binding 
domain, DID Diaphanous inhibitory domain, FH1 Formin homology domain 1, 
FH2 Formin homology domain 2, DAD Diaphanous autoregulatory domain. 
 
Figure 2: Evaluation of commercially available antibodies for their 
specificity to recognise FHOD1. A) Confocal micrographs of transiently 
transfected COS cells either using GFP-FHOD1 (left column) or HA-FHOD3 
(right column; green signal) and counterstaining with the different antibodies 
against FHOD1 (red signal). Only in the left column is yellow signal observed, 
indicating a specific reaction of the antibodies with FHOD1 and no 
crossreaction with its closest relative FHOD3. B) Immunoblot using the 
different anti FHOD1 antibodies on SDS samples from COS cells transiently 
transfected with GFP-FHOD1 (lane 1), HA-FHOD3 (lane 2) or untransfected 
COS cells (lane 3). 
 
Figure 3: The phosphoThr1141 FHOD1 antibody only detects 
overexpressed full length FHOD1 but not C-terminally truncated FHOD1. 
Confocal micrographs of NRC transfected either with GFP-tagged full length 
FHOD1 (left column) or deltaDAD FHOD1 (right column). 	  
 
 
Figure 4: FHOD1 is expressed in the heart. Immunoblot with pM anti 
FHOD1 shows a band with the expected molecular weight in mouse heart and 
tibialis anterior (TA) and to a lesser extent in soleus (A). Immunoblotting with 
a pR antibody against sarcomeric alpha-actinin was used as a loading control 
for the striated muscle samples (B), spleen was used as a positive control for 
FHOD1 expression. 
 
Figure 5: FHOD1 is preferentially located at the intercalated disc. 
Confocal micrographs of frozen sections of mouse heart stained with different 
antibodies against FHOD1. A) pG anti FHOD1 (C14), B) pG anti FHOD1 
(C20), C) pR anti FHOD1 PhosphoThreonine 1141. All FHOD1 antibodies 
(red signal in merge) predominantly delineate the intercalated disc, in addition 
there is an occasional striated pattern apparent. Counterstaining with a mM 
against myomesin (green signal in merge), an M-band protein, suggests that 
this pattern may be Z-disc associated. The nuclei were stained with DAPI 
(blue signal in merge). Scale bar is equivalent to 10 micrometers. 
 
Figure 6: Expression test of different FHOD1 constructs in COS cells. 
Immunoblot with GFP antibodies of SDS samples from COS cells that were 
transiently transfected with the different FHOD1 constructs. A) 12% SDS-
PAGE, B) 7.5% SDS-PAGE. Constructs of the expected molecular weight 
were observed in all samples. Untransfected COS cells were used as a 
negative control (COS). 
 
Figure 7: Overexpressed FHOD1 is mainly located at the cellular 
periphery in NRC. A) Confocal micrographs of NRC after transient 
transfection with either GFP-tagged full length or B) GFP-tagged constitutively 
active (DeltaDAD) FHOD1 (green signal in merge), counterstained with mM 
antibodies against the Z-disc protein alpha-actinin (red signal in merge) and 
against F-actin (visualised with Alexa633-phalloidin, blue signal in merge). 
FHOD1 is mainly located in a diffuse fashion with marked concentration in the 
periphery of the cells. While expression of a constitutively active version of 
FHOD1 does not seem to perturb myofibrillar organisation too much, the cells 
have increased F-actin. Scale bar is equivalent to 10 micrometres. 
 
Figure 8: Subcellular targeting of GFP-tagged FHOD1 subdomains in 
NRC. Confocal micrographs of NRC transfected with different GFP tagged 
fragments of FHOD1 (green signal in merge). Cells were counterstained with 
mM antibodies against sarcomeric alpha-actinin or myomesin (red signal in 
merge) and F-actin was visualised by Alexa633-phalloidin (blue signal in 
merge). A) FH2 domain [642-1031], B) GBD-DID [1-340], C) the GBD [1-116], 
D) DID [117-340], and E) FHOD1 (long version) lacking the GBD (DeltaGBD) 
[117-1191].  FH, formin homology; GBD, GTPase binding domain; DID, 
diaphanous inhibitory domain. Scale bar is equivalent to 10 micrometers. 
While the FH2 domain on its own targets to the Z-disc, GBD-DID and GBD 
show a diffuse localisation with some sarcomeric targeting. DID alone and an 
N-terminally truncated version of FHOD1 have lost all ability to target and are 
found in cytoplasmic aggregates (DID) or in a vesicular pattern (DeltaGBD), 
suggesting that the GBD domain may mediate the subcellular localisation of 
full length FHOD1. Scale bar is equivalent to 10 micrometres. 
 Figure 9: FHOD1 is increased at the intercalated disc in DCM. Confocal 
micrographs of murine (A, MLP KO mice) or human (B) DCM samples (left 
ventricle) in comparison with the respective wildtype or control heart tissue. A) 
FHOD1 was stained in red using a pG anti FHOD1, the M-bands were 
visualised with a mM anti myomesin (green signal in merge) and the 
intercalated discs were stained with pR antibodies against N-RAP (blue signal 
in merge). A) FHOD1 was stained in red using a pR anti FHOD1 
PhosphoThreonine 1141 antibody and the M-bands were visualised with a 
mM anti myomesin (green signal in merge). The nuclei were stained with 
DAPI and are only shown in blue in the merge. Scale bar is equivalent to 10 
micrometres.  
 	  









